During the so-called “Men's Health Month,” the United States Department of Health and Human Services (HHS) announced on June 18, 2026 a measure that promises to redefine access to testosterone replacement therapy (TRT) for millions of men: it asked pharmaceutical companies to rewrite the warning labels that have accompanied these medications for more than a decade.

What exactly changes?

The Food and Drug Administration (FDA), the regulatory arm of the US Department of Health and Human Services (HHS), requested three specific changes to the prescribing information for testosterone:

This decision adds to a previous step: in February 2025 the FDA had already withdrawn the so-called “black box warning” on cardiovascular risk, although at that time it maintained the age-related limitation.

Scientific support invoked

The central rationale for the measure is the TRAVERSE clinical trial, published in 2023 in The New England Journal of Medicine, which followed more than 5,200 men between 45 and 80 years old with heart disease or at high risk for it. The study, designed specifically to assess cardiovascular risk, found no significant increase in major adverse events — such as heart attacks or strokes — among those who used testosterone versus those who received a placebo.

However, the trial itself was not without red flags: participants treated with testosterone had a higher incidence of non-fatal arrhythmias, including atrial fibrillation, a recognized risk factor for stroke, as well as cases of pulmonary embolism.

HHS Secretary Robert F. Kennedy Jr. — who has publicly declared himself a testosterone user — presented the announcement as an evidence-based correction: “During Men's Health Month, we are putting science back at the center of men's health care,” he said in the official statement. From the FDA, its acting director of the Center for Drug Evaluation and Research, Michael Davis, maintained that the agency's responsibility is to keep prescribing information aligned with the available scientific evidence.

An expanding industry

That commercial context fuels much of the debate: As the “hormonal wellness” market grows, regulators are trying to draw the line between a legitimate medical therapy and a mass consumer fad.

Documented benefits, but with nuances

Specialists consulted by various media agree that TRT can improve sexual desire, increase muscle mass, reduce body fat, and stabilize mood and energy levels in men with diagnosed hypogonadism—a condition that, according to estimates cited in news coverage, affects about 35% of men over 45 years of age. Testosterone levels begin to decline naturally after age 35, and excess body fat can accelerate this decline, creating a cycle that makes weight loss even more difficult.

However, doctors such as urologist Jamin Brahmbhatt of Orlando Health warn that removing a warning from the label is not the same as recommending the treatment to any man: Testosterone is still a medical therapy, not an over-the-counter wellness product, and its prescription should require confirmed clinical diagnosis and continuous monitoring of markers such as hematocrit and prostate-specific antigen.

Doubts persist

HHS itself acknowledges in its statement that “significant uncertainties remain,” as prostate cancer can take years to develop and available studies may not have followed patients long enough to detect long-term effects. Therefore, even under the proposed new labels, it would be recommended to maintain risk assessment, pretreatment screening, and medical follow-up throughout therapy.

This is not the first time the current administration has loosened restrictions on hormone therapies: It pushed for a similar move last year regarding menopausal hormone therapy, when the FDA removed black box warnings from those products.

An open debate

So far, the FDA's proposed changes have not been officially implemented; This is a request to manufacturers to modify the labeling, a process that has yet to be completed. Meanwhile, the medical community remains divided between those celebrating a long-awaited update, aligned with the latest evidence, and those who fear that removing warnings will open the door to indiscriminate use of a therapy that, despite the reassuring data from the TRAVERSE trial, is not risk-free.

The underlying question—how healthy it is, in real terms, to artificially raise testosterone levels in men—does not yet have a univocal answer. What does seem clear is that, in the United States, this response will begin to be defined not only in laboratories, but also in the regulatory and commercial field.

You may also be interested in:

Cyclospora: a group of parasites that wreaks havoc through contamination of agricultural products CDC urges people to prevent mosquito bites: here's why Inappropriate prescription: patients with sinusitis often receive antibiotics, even when they don't need them